Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019050759) COMBINATION THERAPY OF LASMIDITAN AND A CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/050759 International Application No.: PCT/US2018/048730
Publication Date: 14.03.2019 International Filing Date: 30.08.2018
IPC:
A61K 31/4545 (2006.01) ,A61P 25/06 (2006.01) ,A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
4545
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
06
Antimigraine agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285, US
Inventors:
AURORA, Sheena; US
JOHNSON, Kirk Willis; US
KREGE, John Henry; US
Agent:
WOOD, Dan L.; US
COMBS, Tonya L.; US
Priority Data:
62/554,72606.09.2017US
Title (EN) COMBINATION THERAPY OF LASMIDITAN AND A CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE
(FR) POLYTHÉRAPIE DE LASMIDITAN ET D'UN ANTAGONISTE DU CGRP POUR UNE UTILISATION DANS LE TRAITEMENT DE LA MIGRAINE
Abstract:
(EN) The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
(FR) La présente invention concerne des combinaisons de lasmiditan et d'un antagoniste du peptide lié au gène de la calcitonine (CGRP), par exemple la combinaison de lasmiditan et de galcanezumab, et des méthodes d'utilisation des combinaisons pour le traitement de la migraine, particulièrement, pour traiter la migraine mal contrôlée par lasmiditan ou une thérapie par antagoniste du CGRP, et plus particulièrement pour traiter une migraine résistante à la thérapie qui est définie dans la description en tant que migraine réfractaire à au moins deux schémas thérapeutiques précédents en monothérapie et/ou double thérapie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)